ARTICLE | Company News
Antex Biologics other research news
September 30, 1996 7:00 AM UTC
ANTX received a $76,000 Phase I SBIR from the U.S. Department of Defense to develop a diagnostic to detect Campylobacter enteritis and Shigella dysentery. The company has developed VeroTest, a recepto...